Razuprotafib

N/A

Report date: 2025/11/05 20:01:16
NME

Base Information

Drug NameRazuprotafib
Drug Alias NameAKB-9778EYP-2301
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor-type tyrosine-protein phosphatase beta inhibitors
TargetsReceptor-type tyrosine-protein phosphatase beta
Therapy Area/IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Retinal Vein Occlusion +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProcter & Gamble Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEyepoint Pharmaceuticals IncAerpio Therapeutics Llc
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Retinal Vein Occlusion +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBank